FindTrial
Sign In

The effect of the addition of D-cycloserine to exposure sessions in the treatment of patients with obsessive-compulsive disorder. A randomized, placebo-controlled trial.

The effect of the addition of D-cycloserine to exposure sessions in the treatment of patients with obsessive-compulsive disorder. A randomized, placebo-controlled trial.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-000367-18-NL
Enrollment
Unknown
Registered
2007-04-17
Start date
2007-07-12
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-Compulsive Disorder MedDRA version: 9.1 Level: LLT Classification code 10029898 Term: Obsessive-compulsive disorder

Interventions

Trade Name: cycloserine Pharmaceutical Form: Capsule* Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use

Sponsors

Meerkanten GGz
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients with a primary DSM-IV diagnosis of OCD with an age of 18 years and older as established with the Structural Clinical Interview for axis I DSM-IV Disorders (SCID I) - Obsessive-compulsive complaints has to be such that exposure in vivo is feasible at the outpatient department, in the clinic or the direct environment. - Patients have to understand the rationale of exposure therapy and there has to be a readiness to participate in exposure sessions. - If a patient uses medication, dosages have to be stable (no changes in the last 2 months and during the study period). - Negative pregnancy test (ß-HCG in urine). Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Addiction to alcohol or drugs or abuse of these compounds - A primary diagnosis of a personality disorder - Psychotic disorder - Relevant somatic disorders - Suicidal intentions - Pregnancy or breastfeeding - Usage of medication possibly interfering with DCS (isoniazide, protonionamide)

Design outcomes

Primary

MeasureTime frame
Main Objective: The aim of this pilot-study is to establish the potential efficacy of D-cycloserine (DCS), a partial NMDA agonist, in accelerating and/or augmenting the effect of exposure and response prevention (ERP) in the treatment of obsessive-compulsive disorder (OCD).;Secondary Objective: Are the effects of D-cycloserine, if established, maintained in a follow-up period of 3 months?;Primary end point(s): Acceleration of the treatment effect of ERP is taken as the primary outcome measure. The differences in scores on the Y-BOCS (clinical interview) between baseline and at several time points will be taken as the main measurement—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026